CRS

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Friday, September 24, 2021 - 1:30pm

Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).

Key Points: 
  • Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • We will diligently advance the clinical development of RJX and evaluate its benefit for COVID-19 patients, said Fatih Uckun, MD PhD, the Chief Medical Officer of Reven.
  • It is currently being evaluated as a COVID-19 drug candidate in high risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

Tencent Cloud Launches Global V+ Challenge In Line With Digitalization Trends

Thursday, September 23, 2021 - 8:16am

In view of these developments, Tencent Cloud, the cloud business of Tencent, today announced the launch of a new initiative called V+ Challenge (Global Innovation and Entrepreneurship Challenge for V+ Real-Time Internet), a global audio/ video solutions contest that calls on participants to innovate on use cases and best practices based on Tencent Cloud's high-quality audio and video cloud technologies.

Key Points: 
  • In view of these developments, Tencent Cloud, the cloud business of Tencent, today announced the launch of a new initiative called V+ Challenge (Global Innovation and Entrepreneurship Challenge for V+ Real-Time Internet), a global audio/ video solutions contest that calls on participants to innovate on use cases and best practices based on Tencent Cloud's high-quality audio and video cloud technologies.
  • Tencent Cloud has also been supporting 90% of China's audio and video customers in their cloud-based innovation.
  • For overseas businesses, Tencent Cloud has adapted targeted, localized technology and algorithms to meet the unique needs of individual regions and markets.
  • Tencent Cloud is Tencent's cloud services brand, providing industry-leading cloud products and services to organizations and enterprises across the world.

HS Management Partners, LLC Expands Business Development & Marketing

Wednesday, September 22, 2021 - 1:10pm

NEW YORK, Sept. 22, 2021 /PRNewswire/ --Concentrated quality boutique investment firm HS Management Partners, LLC, (HSMP) is expanding its business development and marketing efforts with the hiring of Tomas A. Bylaitis as Senior V.P., Head of Business Development, and the internal appointment of Patti Norton in the new role of Senior V.P., Client Marketing.

Key Points: 
  • NEW YORK, Sept. 22, 2021 /PRNewswire/ --Concentrated quality boutique investment firm HS Management Partners, LLC, (HSMP) is expanding its business development and marketing efforts with the hiring of Tomas A. Bylaitis as Senior V.P., Head of Business Development, and the internal appointment of Patti Norton in the new role of Senior V.P., Client Marketing.
  • HSMP's Composite performance (through 8/31/21) has delivered 13.7% annualized growth net-of-fees since inception and will soon reach the 15-year mark (3/31/22).
  • He joins us from Keeley-Teton Advisors, a Chicago-based asset manager where he led their sales team.
  • For additional information on HS Management Partners, please visit our website at www.hsmanage.com which includes an informational video about the Firm or contact us at 212-888-0060or info@hsmanage.com .

Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

Tuesday, September 21, 2021 - 12:00pm

WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that the positive results of the Company’s Phase 2 LANTERN study of LYR-210 were published online in the peer-review journal, International Forum of Allergy & Rhinology. The manuscript titled, “Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study,” can be accessed online here.

Key Points: 
  • The manuscript titled, Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study, can be accessed online here .
  • The LANTERN study evaluated the safety and efficacy of LYR-210 in surgically nave CRS patients who had failed previous medical management.
  • I believe that LYR-210 has the potential to completely transform the CRS treatment paradigm.
  • Lyra Therapeutics, Inc.is a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.

Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data

Monday, September 20, 2021 - 12:00pm

Lyras XTreo platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex.

Key Points: 
  • Lyras XTreo platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric matrix and a versatile polymer-drug complex.
  • Lyras lead product candidate, LYR-210, is entering Phase 3 clinical development for the treatment of chronic rhinosinusitis (CRS) as an alternative to primary sinus surgery.
  • Lyras second product candidate, LYR-220, is entering Phase 2 development and is designed to be an alternative to revision CRS sinus surgery and post-surgical medical management.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

Monday, September 20, 2021 - 1:24am

Results of this trial have been orally presented at the European Society of Medical Oncology Congress 2021 (ESMO 2021).

Key Points: 
  • Results of this trial have been orally presented at the European Society of Medical Oncology Congress 2021 (ESMO 2021).
  • Major treatments for advanced gastric cancer are chemotherapy and HER2-targeted therapy, but the percentage of HER2 positive patients in gastric cancer is only 7-20%.
  • Professor Lin Shen of Beijing Cancer Hospital commented that, "Gastric cancer is of high incidence globally and particularly in Asia.
  • Data presented at ESMO showed significant efficacy and excellent tolerability of CT041 and we hope that it could benefit more cancer patients."

Lumino Ceremony Uses a Combination of Zero-Knowledge Proof and Blockchain to Solve the Limitations of Privacy and Data Security

Sunday, September 19, 2021 - 3:31am

Therefore, trusted computing uses cryptography such as zero-knowledge proof to complete data calculation while ensuring data privacy.

Key Points: 
  • Therefore, trusted computing uses cryptography such as zero-knowledge proof to complete data calculation while ensuring data privacy.
  • Cryptographic algorithms represented by zero-knowledge proof provide a solution for data security and privacy.
  • Since then, other blockchain systems have also added zero-knowledge proof to verify while protecting user/transaction privacy.
  • In Platon/Alaya's world, Lumino is a multi-party collaborative computing ceremony that creates the necessary security parameters for one of Platon/Alaya's cryptographic infrastructures, the Zero-knowledge Proof Protocol.

TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors

Friday, September 17, 2021 - 12:30pm

15 of the 16 patients evaluable for efficacy experienced regression of their target lesions, ranging in magnitude from 5% to 75%.

Key Points: 
  • 15 of the 16 patients evaluable for efficacy experienced regression of their target lesions, ranging in magnitude from 5% to 75%.
  • One patient with cholangiocarcinoma was also considered to have achieved a PR by investigator assessment, for an ORR of 31%.
  • Patients with treatment refractory cancer have very limited treatment options and will often need hospice and supportive care.
  • Our ambition with gavo-cel from the start was to redefine treatment for solid tumors with cell therapies.

Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

Thursday, September 16, 2021 - 8:30am

We look forward to moving into expansion cohorts and to expanding our clinical development plan to include combination with standard-of-care trastuzumab-containing regimens.

Key Points: 
  • We look forward to moving into expansion cohorts and to expanding our clinical development plan to include combination with standard-of-care trastuzumab-containing regimens.
  • As of August 1, 2021, 40 patients with advanced or metastatic HER2-expressing or amplified solid tumors were enrolled into the SBT6050-101 trial.
  • The signals of anti-tumor activity are encouraging and its complementary mechanism of action with standard-of-care agents makes SBT6050 attractive for combination regimens.
  • SBT6050 is currently being evaluated in a Phase 1/1b trial in patients with advanced or metastatic HER2-expressing or amplified solid tumors.

Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors

Thursday, September 16, 2021 - 7:30am

ALAMEDA, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care, today reported new interim data from an ongoing Phase 1 dose escalation study demonstrating feasibility with ACE1702, the company’s most advanced investigational antibody effector cell therapy (ACE), in development for patients with advanced HER2-positive tumors. Initial results from this first-in-human study show that repeat dosing of ACE1702 was safe and well-tolerated across the first four dose levels, comprising 9 billion cells per cycle at dose level four (DL4). No clinical signs of dose limiting toxicity (DLT), such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or graft versus host disease (GvHD) have been reported so far.

Key Points: 
  • As the study advances, we will work to determine optimal dosing for this investigational drug and continue to explore its therapeutic potential.
  • The ACC platform, combined with Acepodias proprietary immune effector cells, increases binding strength against tumors that express low levels of tumor antigens to prevent tumor cell escape.
  • The antibody cell effector (ACE) therapy, ACE1702, expresses high levels of multiple natural killer (NK) cell activation and signaling receptors, including CD16, with limited expression of inhibitory receptors.
  • Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care.